Bisantrene is primarily used in the field of oncology as an antineoplastic agent. It is employed in the treatment of various types of cancer, particularly in cases where other chemotherapy drugs have proven ineffective. Its mechanism of action involves intercalating into DNA, thereby inhibiting the replication process of cancer cells and leading to their destruction. Bisantrene has shown efficacy in managing certain leukemias and solid tumors, making it a valuable option in clinical settings where alternative treatments are limited. Additionally, its relatively lower cardiotoxicity compared to some other anthracenedione derivatives makes it a preferable choice in specific patient populations. Research continues to explore its potential in combination therapies and its effectiveness against drug-resistant cancers.